Hair Women
Food supplement declared in France, decision dated 18 June 2026
Hair Women, from Laboratoire Therascience Luxembourg, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: cystine 500 mg per day, kératine 300 mg per day, méthionine 150 mg per day, Panicum miliaceum 200 mg per day, Serenoa repens 180 mg per day. 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- Laboratoire Therascience Luxembourg
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 3 gélules par jour
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, History of breast cancer, Children (under 12), Pregnant women, Kidney failure, Heart problems, Taking medication
Declaration 368128, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Panicum miliaceum L. | Graine | Extrait sec hydroalcoolique | 200 mg |
| Serenoa repens (W.Bartram) Small | Fruit | Extrait sec hydroalcoolique | 180 mg |
| Equisetum arvense L. | Parties aériennes | Extrait sec hydroalcoolique | 120 mg |
| Trifolium pratense L. | Parties aériennes | Extrait sec hydroalcoolique | 100 mg |
| Sedum roseum (L.) Scop. | Racine | Extrait sec hydroalcoolique | 100 mg |
Substances
| Name | Per day |
|---|---|
| cystine | 500 mg |
| kératine | 300 mg |
| méthionine | 150 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Oléorésine riche en astaxanthine extraite de l’algue Haematococcus pluvialis | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| calcium-L-methylfolate | Folate (vitamin B9) | 1,000 µg | 200 µg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| L-selenomethionine | Selenium | 255 µg | 50 µg |
| thiamin mononitrate | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| methylcobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| Riboflavine 5'-phosphate | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxal 5′-phosphate | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| D-alpha-tocopheryl acetate | Vitamin E | 300 mg | 30 mg |
| zinc bisglycinate | Zinc | 25 mg | 15 mg |
Additives
E464
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Regulatory points
- Conditions légales
Trifolium pratense L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Serenoa repens (W.Bartram) Small
Read the warning, when it applies and the studies cited
SAW PALMETTO – SERENOA REPENS
Route of administration: Oral
Cautions and warnings
Condition of application: All subpopulations.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Adult males only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.
Condition of application: Adult females only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
Contraindications
Condition of application: Adult females only.
Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
- Sedum roseum (L.) Scop.
Read the warning, when it applies and the studies cited
RHODIOLA - RHODIOLA ROSEA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024: 20 March 2024 EMA/HMPC/24177/2023 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Rhodiola rosea L., rhizoma et radix Final - Revision 1. Amsterdam (NL): European Medicines Agency, Science Medicines Health. [Accessed 2025 January 21]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, hormone replacement therapy (HRT) or birth control medication (HC 2018; Iovieno et al. 2011; Olsson et al. 2009; Brown et al. 2002).
Sources cited by Health Canada (4)
- Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
- HC 2018: Health Canada. Canada Vigilance Adverse Reaction Online Database. Ottawa (ON): Marketed Health Products Directorate, Health Canada. [Accessed 2025 January 21]. Available from: https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp
- Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
- SC 2018: Santé Canada. Base de données en ligne des effets indésirables de Canada Vigilance. Ottawa (ON): Direction des produits de santé commercialisés, Santé Canada. [Consulté le 21 janvier 2025]. Disponible à : https://cvp-pcv.hc-sc.gc.ca/arq-rei/switchlocale.do?lang=fr&url=t.search.recherche
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you have bipolar disorder or bipolar spectrum disorder (Iovieno et al. 2011; Winston and Maimes 2007; Brown et al. 2002).
Sources cited by Health Canada (3)
- Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
- Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
- Winston D, Maimes S. Adaptogens: Herbs for Strength, Stamina, and Stress Relief. Rochester (VT): Healing Arts Press, 2007.
Known adverse reactions
Stop use if you experience irritability or insomnia (Pizzorno and Murray 2006; Kelly 2001).
Sources cited by Health Canada (2)
- Kelly GS. Rhodiola rosea: A Possible Plant Adaptogen. Alternative Medicine Review 2001;6(3): 293-302. PubMed Review article
- Pizzorno JE, Murray MT, editors. Textbook of Natural Medicine. 3rd edition, volume 1. St. Louis (MI): Churchill Livingstone Elsevier; 2006.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Hair Women: composition and regulation”, https://compoatlas.com/en/supplements/products/368128-hair-women, updated 15 November 2026.